Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Up 18.9 %

NASDAQ MCRB traded up $0.11 on Tuesday, reaching $0.69. The company had a trading volume of 4,379,300 shares, compared to its average volume of 4,322,203. The stock has a market capitalization of $117.54 million, a PE ratio of -2.99 and a beta of 2.06. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $2.05. The firm’s 50 day moving average price is $0.83 and its 200 day moving average price is $0.91.

Institutional Investors Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MCRB. FMR LLC increased its position in shares of Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Vanguard Group Inc. boosted its stake in Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after buying an additional 729,514 shares during the period. Geode Capital Management LLC increased its position in Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after acquiring an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 222,771 shares during the period. Finally, Vontobel Holding Ltd. bought a new stake in shares of Seres Therapeutics in the 3rd quarter worth about $374,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.